Intervention Review

You have full text access to this OnlineOpen article

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

  1. Theresa A Lawrie1,
  2. Andrew Bryant2,
  3. Alison Cameron3,*,
  4. Emma Gray4,
  5. Jo Morrison5

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 9 JUL 2013

Assessed as up-to-date: 2 JUL 2013

DOI: 10.1002/14651858.CD006910.pub2

How to Cite

Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD006910. DOI: 10.1002/14651858.CD006910.pub2.

Author Information

  1. 1

    Royal United Hospital, Cochrane Gynaecological Cancer Group, Bath, UK

  2. 2

    Newcastle University, Institute of Health & Society, Newcastle upon Tyne, UK

  3. 3

    University Hospitals Bristol NHS Foundation Trust, Department of Clinical Oncology, Bristol, UK

  4. 4

    Musgrove Park Hospital, The Beacon Centre, Taunton, Somerset, UK

  5. 5

    Musgrove Park Hospital, Department of Obstetrics and Gynaecology, Taunton, Somerset, UK

*Alison Cameron, Department of Clinical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre, Horfield Road, Bristol, BS2 8ED, UK. Alison.Cameron@UHBristol.nhs.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 9 JUL 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram of searches to 15 October 2012.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 PLD/carbo vs carbo ± other, Outcome 1 PFS.
[Analysis 1.2]
Analysis 1.2. Comparison 1 PLD/carbo vs carbo ± other, Outcome 2 OS.
[Analysis 1.3]
Analysis 1.3. Comparison 1 PLD/carbo vs carbo ± other, Outcome 3 SAE: Hand-foot syndrome (G3).
[Analysis 1.4]
Analysis 1.4. Comparison 1 PLD/carbo vs carbo ± other, Outcome 4 SAE: Anaemia (G3/4).
[Analysis 1.5]
Analysis 1.5. Comparison 1 PLD/carbo vs carbo ± other, Outcome 5 SAE: Febrile neutropenia (G3/4).
[Analysis 1.6]
Analysis 1.6. Comparison 1 PLD/carbo vs carbo ± other, Outcome 6 SAE: Neutropenia (G3/4).
[Analysis 1.7]
Analysis 1.7. Comparison 1 PLD/carbo vs carbo ± other, Outcome 7 SAE: Thrombocytopenia (G3/4).
[Analysis 1.8]
Analysis 1.8. Comparison 1 PLD/carbo vs carbo ± other, Outcome 8 SAE: Stomatitis/mucositis (G 3/4).
[Analysis 1.9]
Analysis 1.9. Comparison 1 PLD/carbo vs carbo ± other, Outcome 9 SAE: Vomiting (G 3/4).
[Analysis 1.10]
Analysis 1.10. Comparison 1 PLD/carbo vs carbo ± other, Outcome 10 SAE: Alopecia (G2).
[Analysis 1.11]
Analysis 1.11. Comparison 1 PLD/carbo vs carbo ± other, Outcome 11 SAE: Neurological (G3/4).
[Analysis 1.12]
Analysis 1.12. Comparison 1 PLD/carbo vs carbo ± other, Outcome 12 SAE: Fatigue (G3/4).
[Analysis 1.13]
Analysis 1.13. Comparison 1 PLD/carbo vs carbo ± other, Outcome 13 SAE: Arthralgia/myalgia (G3/4).
[Analysis 1.14]
Analysis 1.14. Comparison 1 PLD/carbo vs carbo ± other, Outcome 14 SAE: Hypersensitivity reactions (HSR; G3/4).
[Analysis 1.15]
Analysis 1.15. Comparison 1 PLD/carbo vs carbo ± other, Outcome 15 SAE: Treatment-related death.
[Analysis 1.16]
Analysis 1.16. Comparison 1 PLD/carbo vs carbo ± other, Outcome 16 QoL: Global health score (mean change).
[Analysis 1.17]
Analysis 1.17. Comparison 1 PLD/carbo vs carbo ± other, Outcome 17 Discontinuation due to toxicity.
[Analysis 1.18]
Analysis 1.18. Comparison 1 PLD/carbo vs carbo ± other, Outcome 18 Antibiotics required.
[Analysis 1.19]
Analysis 1.19. Comparison 1 PLD/carbo vs carbo ± other, Outcome 19 G-CSF required.
[Analysis 1.20]
Analysis 1.20. Comparison 1 PLD/carbo vs carbo ± other, Outcome 20 Blood transfusion required.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Other drug vs PLD, Outcome 1 PFS.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Other drug vs PLD, Outcome 2 OS.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Other drug vs PLD, Outcome 3 SAE: HFS (G3).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Other drug vs PLD, Outcome 4 SAE: Stomatitis (G3/4).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Other drug vs PLD, Outcome 5 SAE: Neutropenia (G3/4).
[Analysis 2.6]
Analysis 2.6. Comparison 2 Other drug vs PLD, Outcome 6 SAE: Anaemia (G3/4).
[Analysis 2.7]
Analysis 2.7. Comparison 2 Other drug vs PLD, Outcome 7 SAE: Thrombocytopenia (G3/4).
[Analysis 2.8]
Analysis 2.8. Comparison 2 Other drug vs PLD, Outcome 8 SAE: Vomiting (G3/4).
[Analysis 2.9]
Analysis 2.9. Comparison 2 Other drug vs PLD, Outcome 9 SAE: Fatigue/asthenia (G3/4).
[Analysis 2.10]
Analysis 2.10. Comparison 2 Other drug vs PLD, Outcome 10 SAE: Neurological (G3/4).
[Analysis 2.11]
Analysis 2.11. Comparison 2 Other drug vs PLD, Outcome 11 SAE: Alopecia (G2).
[Analysis 2.12]
Analysis 2.12. Comparison 2 Other drug vs PLD, Outcome 12 SAE: Allergy (G3/4).
[Analysis 2.13]
Analysis 2.13. Comparison 2 Other drug vs PLD, Outcome 13 SAE: Diarrhoea (G3/4).
[Analysis 2.14]
Analysis 2.14. Comparison 2 Other drug vs PLD, Outcome 14 Dose reductions.
[Analysis 2.15]
Analysis 2.15. Comparison 2 Other drug vs PLD, Outcome 15 Dose delays.
[Analysis 3.1]
Analysis 3.1. Comparison 3 PLD + other drug vs PLD, Outcome 1 PFS.
[Analysis 3.2]
Analysis 3.2. Comparison 3 PLD + other drug vs PLD, Outcome 2 PFS: PPS subgroup only.
[Analysis 3.3]
Analysis 3.3. Comparison 3 PLD + other drug vs PLD, Outcome 3 OS.
[Analysis 3.4]
Analysis 3.4. Comparison 3 PLD + other drug vs PLD, Outcome 4 SAE: Anaemia (G3/4).
[Analysis 3.5]
Analysis 3.5. Comparison 3 PLD + other drug vs PLD, Outcome 5 SAE: Neutropenia (G3/4).
[Analysis 3.6]
Analysis 3.6. Comparison 3 PLD + other drug vs PLD, Outcome 6 SAE: Thrombocytopenia (G3/4).
[Analysis 3.7]
Analysis 3.7. Comparison 3 PLD + other drug vs PLD, Outcome 7 SAE: Vomiting (G3/4).
[Analysis 3.8]
Analysis 3.8. Comparison 3 PLD + other drug vs PLD, Outcome 8 SAE: HFS (G3).
[Analysis 3.9]
Analysis 3.9. Comparison 3 PLD + other drug vs PLD, Outcome 9 SAE: Stomatitis (G3/4).
[Analysis 3.10]
Analysis 3.10. Comparison 3 PLD + other drug vs PLD, Outcome 10 SAE: Alopecia (G2).
[Analysis 3.11]
Analysis 3.11. Comparison 3 PLD + other drug vs PLD, Outcome 11 SAE: Abdominal pain (G3/4).
[Analysis 3.12]
Analysis 3.12. Comparison 3 PLD + other drug vs PLD, Outcome 12 SAE: Neuropathy (G3/4).
[Analysis 3.13]
Analysis 3.13. Comparison 3 PLD + other drug vs PLD, Outcome 13 SAE-related death.
[Analysis 3.14]
Analysis 3.14. Comparison 3 PLD + other drug vs PLD, Outcome 14 Dose reductions.
[Analysis 3.15]
Analysis 3.15. Comparison 3 PLD + other drug vs PLD, Outcome 15 Dose delays.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Exploratory analyses, Outcome 1 SAE: HFS (G3) subgrouped by PLD dose.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Exploratory analyses, Outcome 2 SAE: Stomatitis (G3/4).